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Abstract
This study aimed to re-evaluate the possible differences between attention-deficit/hyperactivity disorder (ADHD) subjects and
healthy controls in the context of a standard Go/NoGo task (visual continuous performance test [VCPT]), frequently used to
measure executive functions. In contrast to many previous studies, our sample comprises children, adolescents, and adults. We
analyzed data from 447 ADHD patients and 227 healthy controls. By applying multivariate linear regression analyses, we con-
trolled the group differences between ADHD patients and controls for age and sex. As dependent variables we used behavioral
(number of omission and commission errors, reaction time, and reaction time variability) and neurophysiological measures
(event-related potentials [ERPs]). In summary, we successfully replicated the deviations of ADHD subjects from healthy controls.
The differences are small to moderate when expressed as effect size measures (number of omission errors: d= 0.60, reaction time
variability: d= 0.56, contingent negative variation (CNV) and P3 amplitudes: −0.35 < d<−0.47, ERP latencies: 0.21< d<0.29).
Further analyses revealed no substantial differences between ADHD subtypes (combined, inattentive, and hyperactive/impulsive
presentation), subgroups according to high- and low-symptomatic burden or methylphenidate intake for their daily routine. We
successfully replicated known differences between ADHD subjects and controls for the behavioral and neurophysiological variables.
However, the small-to-moderate effect sizes limit their utility as biomarkers in the diagnostic procedure. The incongruence of self-
reported symptomatic burden and clinical diagnosis emphasizes the challenges of the present clinical diagnosis with low reliability,
which partially accounts for the low degree of discrimination between ADHD subjects and controls.
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Introduction
According to the Diagnostics and Statistical Manual of Mental
Disorders, fifth edition (DSM-5), ADHD is a developmental
disorder characterized by inappropriate levels of attention and
limitations in executive functioning. Although symptoms may
alter over the lifespan, functional impairment persists for
many individuals into adulthood.1,2 Since the clinical diagnosis
of ADHD has shown only moderate reliability, validity, and
objectivity, research is trying to identify behavioral and neuro-
physiological markers to complement the current diagnostic
procedure and to improve the understanding of the neural
underpinnings of ADHD.3-5
A frequently used behavioral paradigm is the VCPT, a clas-
sical Go/NoGo task. This paradigm assesses executive func-
tions, including sustained attention, alertness, and inhibition.
Most studies using such paradigms report reduced cognitive
performance of subjects with ADHD,6-11 such as increased
omissions and commission errors.9,12 The number of commis-
sion errors is often referred to as a lack of inhibitory control
or impulsivity, whereas the number of omission errors is asso-
ciated with inattention.13 The most robust behavioral measure
discriminating ADHD and control subjects is reaction time var-
iability, which is mostly larger in ADHD subjects.11,14,15
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Furthermore, alterations in executive functions are reflected
by deviating neurophysiological processing of the perceived
stimuli, represented by the amplitude and latency of the
ERPs. Subjects with ADHD show generally attenuated ampli-
tudes and increased latencies in several positive and negative
deflections.4,16-18
These behavioral and neurophysiological measures are often
used as biomarkers to identify ADHD subjects. On an individ-
ual level, they provide valuable information about neuronal
processing and executive functions.19,20 For example, P3
deflections are related to attentional resources and reorienta-
tion,21 whereas the late CNV reflects task-set representation22
and anticipatory attention.23 The NoGo and Go trials’ ERP dif-
ference curve was associated with conflict detection (N2d) and
inhibition of action (P3d).16,24
In this study, we are re-evaluating the question, whether and
how strong typical behavioral and neurophysiological metrics
of executive functions differ between subjects diagnosed as
ADHD and healthy controls. We hypothesize that ADHD sub-
jects will demonstrate an increased number of errors, increased
reaction time variability, attenuated ERP amplitudes, and
increased ERP latencies. A particular aspect of our study is
the large cohort of over 650 subjects, comprising children, ado-
lescents, and adults. With this large sample, we are in a position
to compute robust statistical metrics for group differences
between ADHD and controls, and investigate the potential
interaction of group and age categories.
Methods
Subjects robust
Data were taken from a large-scale multicenter clinical study
that includes n= 447 ADHD patients and n= 227 healthy con-
trols (total number of available subjects: n= 674). The subjects’
age range is 6 to 60 years (mean and standard deviation: 19.0±
13.8 years). Overall, n= 212 children aged 6-13 years (ADHD:
n= 149; 10.2± 1.7 years; controls: n= 63, 9.9± 1.7 years),
n= 107 adolescents aged 13-18 years (ADHD: n= 88; 14.9±
1.4 years; controls: n= 19, 16.6± 1.6 years), and n= 355
adults (ADHD: n= 210; 34.4± 10.1 years; controls: n= 145,
28.8± 11.9 years) were included.
Data were collected in 2014 and 2015 as the baseline assess-
ment of a longitudinal project lasting 2 years. The ADHD sub-
jects were diagnosed by certified psychiatrists and clinical
psychologists according to the DSM-5. Fluid intelligence was
assessed by the standard IQ paper and pencil test (<9 years,
CFT 1-R25; 9-16 years, CFT 20-R part I25; >16 years,
WMT-226). General exclusion criteria for the study were trau-
matic brain injury, loss of consciousness in the past, another
primary mental disorder (e.g., depression and schizophrenia),
drug abuse, pregnancy, epilepsy, and an IQ< 80. The partici-
pants had to be able to follow the study instructions in
German and provide informed consent. All subjects have
been medication-free on the day of the assessment. However,
n= 139 (31%) of the ADHD subjects took methylphenidate
comprising medication for their daily routine (e.g., Ritalin,
Concerta, Elvanse). Hundred and ninety-two subjects did not
use methylphenidates (n= 192, 43%), while for n= 116
(26%) information was missing.
Descriptive information of the subjects is shown in Table 1.
The female-to-male (f/m) ratio is higher in the control than in
the ADHD group (f/m controls= 1.41; f/m ADHD= 0.51; the
odds ratio for this difference is 2.8, 95% confidence interval
[CI]= [2, 3.9]). The subjects of the two groups were on
average of similar age (t[672]= 1.82, P= .07); however, they
differ in terms of IQ scores (t[654]= 654, <0.01, d=−0.41
95% CI= [−0.58, −0.25]).
Subjects with <40% of valid trials (artifact-free electroen-
cephalography [EEG] and no errors) were excluded (n= 55
ADHD and n= 4 controls), resulting in a reduced sample for
all ERP-related analyses (n= 432, ADHD and n= 224 con-
trols). ADHD subjects had less valid trials compared to the con-
trols under Go and NoGo conditions. Median valid trials and
interquartile ranges under the Go condition were 70 [63, 81]
for the control and 60 [50, 73] for the ADHD group
(W= 68001, P< .01, r= 0.2 95% CI= [0.28, 0.35]). Under the
NoGo condition, the values were 84 [79, 92] for the control
and 76 [67, 87] for the ADHD group (W= 67185, P<.01,
r= 0.2 95% CI= [0.26, 0.34]).
As the ADHD clinical diagnosis shows a low reliability,27-29
we cross-checked it with the self-reported questionnaire data
of ADHD symptoms of the DSM-5.30,31 Symptoms experi-
enced “often” or “very often” were dummy coded with 1
and subsequently summed up within the two subscales:
(1) inattention and (2) hyperactivity and impulsivity.
Congruence of the self-reported questionnaire with the clini-
cal diagnosis was achieved if a subject exceeded the threshold
of 6 in children, respectively, 5 in adults within one subscale,
as determined by the DSM-5 as a requirement for the diagno-
sis of ADHD.31 Based on the congruence (yes vs no) between
the clinical diagnosis and the self-report data, we subdivided
the ADHD group into two subgroups: ADHD-1
(yes; n= 346, 77%) and ADHD-2 (no; n= 101, 23%). Please
note that certified clinicians diagnosed all ADHD subjects at
the entry of the study. We determined the ADHD subtype for
Table 1. Demographic Characteristics of the Dataset. The Number
of Male and Female Subjects, and the Means and Standard Deviations
for Age, and IQ are Given.
Control ADHD
n total 227 447
n (%) female 133 (59%) 151 (34%)
n (%) male 94 (41%) 296 (66%)
Age (years) 20.6± 14.1 16.8± 13.7
IQ 109± 13 102± 15
Note: Missing data for IQ: control n= 3, ADHD, n= 15.
Abbreviation: ADHD, attention-deficit/hyperactivity disorder.
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all ADHD subjects with questionnaire data corresponding to
the clinical diagnosis (n= 346); subjects exceeding the
threshold in both subscales (ADHD-combined= 131, 38%),
only in the inattention subscale (ADHD-inattention= 190,
55%), and only in the hyperactivity/impulsivity subscale
(ADHD-hyperactivity/inattention= 25, 7%).
VCPT (Go/NoGo task)
We used a cued Go/NoGo task to assess executive functions,
particularly challenging the sustained attention and inhibitory
control. This task was used in a set of previous
studies.10,20,32,33 The test compromises 400 trials, of which
each consists of a pair of consecutively presented visual
stimuli (animals, plants, and humans). In Go-trials (animal–
animal), a picture of an animal is followed by a picture of an
animal, and the participant is asked to press a button. Failure
of this task results in an omission error. In NoGo trials
(animal–plant), the participant is asked to withhold from press-
ing the button. Failure of this task results in a commission error.
Under the two ignore conditions (plant–plant and plant–
human), no action is required. Each category was presented
equally often (each 25%). Stimulus 1 was presented at
300 ms and stimulus 2 at 1400 ms (inter-stimulus interval=
1000 ms), each for 100 ms. Reaction time variability was com-
puted for all Go trials, defined as the coefficient of variance for
reaction time (standard deviation of mean reaction time divided
by mean reaction time).
Electrophysiology
EEG data were recorded with the NeuroAmp® ×23, a
19-channel EEG system with a 24-bit resolution and a sampling
rate of 500 Hz, which was down-sampled to 250 Hz. The input
signals were bandpass filtered between 0.5 and 50 Hz. The
montage was changed from linked earlobes to common
average reference before processing. Electrodes were placed
according to the International 10-20 system using a fitting elec-
trode cap with tin electrodes (Electro-cap International Inc.).
Impedance was kept below 5 kΩ for all electrodes. Raw EEG
was recorded using the ERPrec software (BEE Medic GmbH)
and processed as well as analyzed using Matlab-based
in-house software. Eye blinks and horizontal eye movements
were detected using independent component analysis decompo-
sition and removed from EEGs by zeroing the activation of the
respective components.34 The remaining artifacts were
removed by rejecting filtered EEG segments with amplitudes
>100 µV and/or excessive activity in the 0-3 and 20-50 Hz fre-
quency bands (threshold= channel z-score of 6).
ERPs
ERP features were extracted using a Matlab-based custom-built
EEGLAB plug-in. After baseline correction using the 100 ms
pre-stimulus period, the peak detection of the ERP components
was determined within the adjusted time windows for three age
groups: children (<13 years), adolescents (13-18 years), and
adults (≥18 years). The point on the ERP waveform at which
it reaches the maximum (or minimum) was determined within
a time window whose size was set to 80% of the time interval
between the component peak of interest and the preceding peak.
For example, if P3 is at 300 ms and N2 at 200 ms, the window
for P3 is fixed from 260 to 340 ms. The problem of inter-
individual temporal differences was dealt with by using self-
modeling warping functions.35 The required minimum
number of valid trials (no artifacts and no errors) is 40 within
one condition, hence 40%. Applying this protocol, we calcu-
lated the amplitudes and latencies of the following ERP
metrics: (1) the P3 after the Go-stimulus (GoP3), (2) the P3
after the NoGo-stimulus (NoGoP3), and (3) the N2 after the
NoGo stimulus (NoGoN2). We also calculated the ERP
metrics of the difference waves between NoGo and Go trials:
(4) P3d and (5) N2d. The (6) CNV amplitude was defined in
the 100 ms window prior to the second stimulus, by the area
under the curve divided by the window size. NoGoP3,
NoGoN2, CNV, P3d, and N2d were measured on electrode
Cz and GoP3 at Pz.
Statistical analysis
The dependent variables for this analysis are the four behavioral
measures (omission errors, commission errors, mean reaction
time, and reaction time variability), as well as the amplitudes
and latencies of the ERPs (GoP3, NoGoP3, NoGoN2, CNV,
P3d, and N2d, without latency for CNV—thus in total 11 var-
iables). We computed multiple linear regressions with the inde-
pendent variables group, age, age category, sex, and the
interactions between age× age category and group× age cate-
gory for all dependent variables. The three categorical variables
were defined as age category (children, adolescents, and
adults), sex (female vs male), and group (ADHD vs controls).
For the number of errors, we applied a log transformation to
reduce skewness. The group differences between ADHD and
controls are described by the multiple regression models’
post-hoc tests, based on the group estimates and the residual
standard error of the model. Therefore, the reported effect
sizes for these group comparisons are controlled for age and
sex. To estimate the relative importance of each independent
variable in explaining the dependent variable, we used the
relaimpo software tool in R using the lmg metric, providing a
decomposition of the total variance explained by the model
into non-negative contributions of each independent variable.36
The necessary assumptions for applying linear regressions (ie,
the approximately normal distribution of the residuals) were
confirmed for the present dataset. All statistical analyses were
carried out with routines from the R software37 on an iMac.
Since statistical tests using such large samples are anti-
conservative revealing significant results (P< .05) even for
very small effects, we use effect size measures (Cohen’s d or
relative importance) to interpret the results. In this context,
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d> 0.2 or R2> 1% is considered as small, d > 0.5 or R2 > 9% as
moderate, and d> 0.8 or R2> 25% as large.38
Results
Mean ERP curves in the Go and NoGo condition are displayed
in Figure 1. In addition, the corresponding difference curve and
the CNV curve are shown.
We computed multiple linear regressions for each dependent
variable of interest, with the group, gender, age, and age cate-
gory, as independent variables, including the interactions: age
× age category and group× age category. With this initial mul-
tiple regression (full model), we identified significant interac-
tions between group and age category for only three
measures: (1) the number of commission errors (P< .001), (2)
the mean reaction time (P= .001), and (3) the latency of
NoGoN2 (P= .022); details of group differences within the
age categories are summarized in the supplementary
Table S1. Since these regressions uncovered that the group×
age category interactions are mainly negligible, we calculated
multiple regression without this interaction (reduced model).
The effect sizes as indicators of the relative importance of the
independent variables are shown in Table 2.
As can be seen from Table 2, all multiple regressions were
significant (P< .05), but substantially differ for the explained
total variances from 3% to 57%. All age-related variables
together (age, age category, and their interaction) explain the
largest part of the variance, whereas sex explains maximally
1%.
The estimates of the independent variables and the results of
the post-hoc tests for group are listed in Table 3. There is
evidence that ADHD subjects commit more omission and
commission errors than controls, present larger variability in
the reaction times, and have attenuated amplitudes and longer
latencies in most of the investigated ERP measures (exception:
NoGoN2 and N2d amplitude). For an overview of the effect
sizes, see Figure 2. Effect sizes (Cohen’s d) reflect the magni-
tude of difference between ADHD subjects and controls; a
Figure 1. ERP curves for the ADHD and control group. The ERPs after the second stimulus (S2) under the Go (animal−animal) and NoGo
conditions (animal−plant), as well as the difference curve, are shown. In addition, the CNV after the first stimulus (S1) under the Go and NoGo
conditions is displayed.
Abbreviations: ERP, event-related potential; ADHD, attention-deficit/hyperactivity disorder.
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positive value in the behavioral measures indicate more errors
and larger reaction time variability for ADHD subjects com-
pared to controls, negative values for the ERP amplitudes indi-
cate attenuated amplitudes for the ADHD subjects compared to
controls and positive values for the ERP latencies indicate
longer latencies for the ADHD subjects compared to controls.
Developmental effects are described by the estimates of the
age-related variables in Table 3. The influence of sex on the
dependent variables is very small (either 1% or below 1%).
Male subjects showed slightly decreased GoP3 and increased
N2d amplitude, and slightly increased GoP3 and N2d, and
decreased P3d latency.
Additional exploratory regression analyses
We conducted subsequent exploratory regression analyses to
examine the influence of additional independent variables on
the outcome measures, which were available only for a subsam-
ple of the dataset. These analyses are based on the reduced
model we have used for our main analysis.
In the first set of subsequent regressions, we added IQ as a
further independent variable. This analysis revealed basically
the same results as the original analyses. The relative impor-
tance of IQ on the dependent variables was small (for the
number of omission errors: 3%; reaction time: 2%; NoGoP3
amplitude: 2%; P3d amplitude: 1%; others: <1%). A higher
IQ was associated with a slightly lower number of omission
errors (intercept= 3.23; IQ: β=−0.01; P< .001), shorter
mean reaction times (intercept= 546; IQ: β=−0.84; P<
.001), and increased NoGoP3 and P3d amplitudes (NoGoP3:
intercept= 5.15, IQ: β= 0.04, P= .006 and P3d: intercept=
5.35, IQ: β= 0.03, P= .025).
The second set of subsequent regressions was performed
exclusively with the subjects of the ADHD group, using meth-
ylphenidate intake in daily life as an additional independent
variable. The explained variance of methylphenidate intake
(categorical variable: yes= 1, no= 0) was <1% for all depen-
dent variables and there was no evidence that the two subgroups
do differ in any of the behavioral or neurophysiological
outcome measures (all P> .05).
The next set of regressions, with a three-level group variable
(ADHD-1, ADHD-2, and controls) did not generally change the
results compared to our main analysis (amount of explained
variance for group and age category was maximally 1%).
The results of the post-hoc group comparisons are shown in
the supplementary Table S2. The effect sizes between controls
to ADHD-1, and controls to ADHD-2 were similar for reaction
time variability. For the number of omission errors and the
attenuation of GoP3, NoGoP3, NoGoN2, and CNV amplitude,
the effect was slightly larger for ADHD-1 compared to controls,
than for ADHD-2 compared to controls. For the P3d amplitude
and N2d latency, the effect was descriptively larger between
ADHD-2 and controls than between ADHD-1 and controls.
There is no evidence for any difference in the direct comparison
between ADHD-1 and ADHD-2.
For the fourth set of subsequent analyses, we subdivided the
ADHD subjects into the three ADHD subtypes proposed by the
DSM-5 (ADHD-combined, ADHD-hyperactivity/impulsivity,
and ADHD-inattention). This regression analyses within the
ADHD subjects revealed evidence for a small influence of
subtype on some of the dependent variables (maximally 2%).
Post-hoc comparisons between subtypes (see Table S3)
revealed only two significant differences, namely reduced reaction
time variability in ADHD-inattention compared to ADHD-
combined (t[337]=−3.17, P=−.005, d=−0.37, 95% CI=
[−0.60, −0.14]) and reduced GoP3 latency in ADHD-inattention
compared to ADHD-hyperactivity/inattention (t[294]= 2.37, P=
.049, d=−0.55, 95% CI= [−1.01, −0.09]).
Discussion
The present study re-evaluates whether ADHD subjects and
healthy control differ in a standard psychological test paradigm
examining executive functions, assessed by a VCPT in associ-
ation with ERPs. We successfully replicated often reported
Table 2. Summary of R2 (As a Percentage of Explained Variance) for
the Reduced Model (R2 Total) and the R2 Values Estimated with
















Omission errors 37* 1 <1 26 5 6
Commission
errors
19* 1 <1 13 <1 5
Reaction time 20* <1 <1 14 5 <1
Reaction time
variability
33* 2 <1 24 1 6
ERP amplitudes
GoP3 29* 1 5 19 1 3
NoGoP3 12* <1 1 4 2 4
NoGoN2 31* 1 3 25 1 1
CNV 3* <1 <1 1 <1 2
P3d 5* 1 1 1 <1 3
N2d 31* 1 5 24 <1 <1
ERP latencies
GoP3 5* <1 1 2 <1 1
NoGoP3 50* 1 1 39 8 1
NoGoN2 57* 1 <1 44 11 1
P3d 27* <1 2 19 4 1
N2d 8* 1 <1 3 1 2
Note: The number of omission and commission errors are transformed by
log(number of errors+ 1). The R2 values are rounded to integer values.
Abbreviations: Age cat, age category (children, adolescents, and adults); Age×
age cat, interaction between age and age category; ERP, event-related potential;
GoP3, P3 after the Go-stimulus; NoGoP3, P3 after the NoGo-stimulus;
NoGoN2, N2 after the NoGo stimulus, P3d and N2d, difference curve between
the NoGo and Go stimulus. *P< .05.
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differences, namely increased number of errors, larger reaction
time variability, attenuated ERP amplitudes, and increased ERP
latencies in ADHD subjects compared to controls.
The magnitude of these group differences, controlled for
age, was small to moderate with effect sizes ranging between
d= 0.2 and d= 0.6. These group differences were comparable
across all age categories, except for the number of commission
errors, mean reaction time, and NoGoN2 latency. Furthermore,
the exploratory analysis showed that ADHD subtypes (ADHD-
combined, ADHD-inattention, and ADHD-hyperactivity/
inattention), and ADHD patients with high and low self-
reported ADHD burden (ADHD-1 and ADHD-2) do generally
not differ in the assessed variables. Furthermore, ADHD sub-
jects taking methylphenidate for their daily routine did not
differ from methylphenidate naive subjects in any behavioral
or neurophysiological outcome measure during the medication-
free assessment. A further finding of our analyses is that higher
IQ scores are associated with slightly fewer omission errors,
shorter mean reaction time, and larger NoGoP3 and P3d
amplitudes.
The small-to-moderate differences between ADHD subjects
and healthy controls in our large sample are basically congruent
with the literature.4,9,11,12,15 We successfully replicated group
differences in this heterogeneous sample, comprising a large
age range, ADHD subjects with different ADHD subtypes,
medication intake, and symptomatic burden. Noteworthy, the
data were collected within a clinical setting with limited exper-
imental control.
We identified generally larger group differences for the
behavioral, than for the ERP measures. The largest effect
sizes were found for the number of omission errors (d=
0.60) and reaction time variability (d= 0.56), which are
similar as reported in the previous meta-analyses (number of
omission errors: Cohen’s d= 0.6712 and reaction time varia-
bility: Hedge’s g= 0.7115). Reaction time variability and
omission errors are supposed to reflect inconsistency in task
performance and a lack of attentional control;15,39 two
major psychological deficits from which ADHD subjects
suffer. Thus, such behavioral measures reflect ADHD defi-
ciencies to a certain degree.
Table 3. Summary of the Coefficients Obtained from the Multiple Regression Analysis (Reduced Model). The Intercepts, the Estimates
Separately for Each Independent Variable, and the Group Contrast ADHD versus Control are Given.
R2 total
(%)
Regression estimates Group contrast
















Omission errors 37* 1.86* −0.68* −1.29* −0.24* 0.15* 0.24* −0.1 0.53* −7.00 <.001* 0.60*
Commission errors 19* 0.79* −0.28* −0.62* 0.01 −0.05 −0.01 0.03 0.35* −5.74 <.001* 0.49*
Reaction time (ms) 20* 453* −71* −78* −21* 15* 22* −6 7 −0.99 .323 0.08
Reaction time
variability
33* 0.28* −0.01 −0.08* 0.01* −0.01* −0.01* 0 0.04* −6.61 <.001* 0.56*
ERP amplitudes
GoP3 29* 13.63* −1.18* −4.42* 0.31* −0.61* −0.43* −0.81* −1.72* 5.39 <.001* −0.47*
NoGoP3 12* 9.83* 2.37* 2.22* 0.68* −0.22 −0.76* −0.4 −2.41* 5.03 <.001* −0.44*
NoGoN2 31* −5.28* 2.32* 4.2* 0.47* −0.06 −0.39* −0.09 −0.54 1.96 .051 −0.17
CNV 3* −1.4 0.01 −0.18 −0.04 0.12 0.04 0.04 0.36* −2.96 <.001* 0.26*
P3d 5* 8.53* −0.09 −1.21* 0.13 −0.45 −0.17 −0.76 −1.53* 3.95 <.001* −0.35*
N2d 31* −8.22* 1.87* 3.94* 0 0.26 0.09 1.0* 0.21 −0.86 .389 0.08
ERP latencies
GoP3 5* 296* 7* 12* −1* 4* 2* 6* 8* −2.38 .017* 0.21*
NoGoP3 50* 404* −68* −61* −13* 10* 14* 0 10* −3.30 <.001* 0.29*
NoGoN2 57* 284* −51* −55* −13* 10* 13* 1 6* −2.84 <.001* 0.25*
P3d 27* 397* −47* −41* −9* 8* 10* −3* 8* −2.41 .016* 0.21*
N2d 8* 245* −12* −10* −3* 4* 4* 7* 8* −3.12 <.001* 0.27*
Note: For the categorical variables group, sex, and age category, the standard procedure for generating dummy variables as provided by the lm package was used and the
number of errors are transformed by log(number of errors+ 1). For the group contrasts ADHD versus controls Cohen’s d effect sizes are averaged over age categories
and sex. Positive effect sizes for negative deflections in the ERP curve (NoGoN2, CNV, and N2d) reflect attenuated ERP amplitudes in ADHD. Negative effect sizes for
positive deflections in the ERP curve (GoP3, NoGoP3, and NoGoN2 and P3d) reflect attenuated ERP amplitudes in ADHD. Details for the variables with evidence for
an interaction of group and age category (number of commission errors, reaction time, and NoGoN2 amplitude) are described in the supplementary Table S1.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; Age cat, age category (children, adolescents, and adults); Age× age cat, interaction between age and age
category; ERP, event-related potential; GoP3, P3 after the Go-stimulus; NoGoP3, P3 after the NoGo-stimulus; NoGoN2, N2 after the NoGo stimulus; P3d and N2d,
difference curve between the NoGo and Go stimulus. *P< .05.
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Age category turned out to affect the number of commission
errors and reaction time. We found differential effects for the
three age categories. The group difference for commission
errors was large for children (d= 1.06) and small for adults (d
= 0.25). Increased commission errors are supposed to reflect a
lack of inhibitory control,12 a functional deficit that is associ-
ated with hyperactive and impulsive symptoms of ADHD.
Interestingly, children with ADHD exhibited faster reaction
times compared to controls (d=−0.37), whereas adults with
ADHD exhibited slower reaction times compared to controls
(d= 0.31). These age-dependent differences between ADHD
and control subjects might be due to a maturational lag in
ADHD subjects, particularly in frontal brain areas involved in
controlling executive functions.40,41
ERP measures are frequently used as biomarkers for execu-
tive functions.16,24,42 In our sample, we identified attenuated
ERP amplitudes and partly increased ERP latencies in ADHD
subjects compared to controls. The effect sizes for the group
comparison of the amplitude measures are comparable to
those reported in a very recent meta-analysis, showing a
small-to-moderate effect for the NoGoP3, GoP3, P3d, and
CNV.4 In contrast to the meta-analysis of Kaiser,4 we found a
moderate group difference for the GoP3 amplitude, which
was comparable in size to the group difference for the
NoGoP3. The P3 deflections are mainly associated with the
allocation of attentional resources, which are deficiently operat-
ing in ADHD subjects.16,21,43
Interestingly, our data also uncovered that higher IQ scores
are associated with increased NoGoP3 and P3d amplitudes. We
suspect that this indicates larger cognitive resources in subjects
with higher IQ, indicating potential coping strategies for atten-
tional deficits.44,45 This is in line with the observed lower
number of omission errors in subjects with higher IQ in our
sample.
Subgroup analyses to address ADHD heterogeneity (methyl-
phenidate intake, symptomatic burden, and ADHD subtypes)
did not exhibit substantial subgroup differences.
We found that the neurophysiological characteristics and
behavioral performance are comparable between subjects
taking methylphenidate for their daily routine and medication-
naive subjects. This comparison has to be differentiated from
discontinuation studies, where subjects stopping stimulant
intake show deleterious performance and well-being compared
to the continuation group.46,47 Details about other strategies to
handle the ADHD symptoms, such as psychotherapy, neuro-
feedback, or other therapeutic options, are not known for the
sample.
The incongruence between the self-reported symptomatic
burden and the clinical diagnosis (ADHD-1 and ADHD-2)
emphasizes the challenges in ADHD research: the clinical clas-
sification is far from being highly reliable and valid.27,29
This study has several limitations: First, the sample com-
prises unbalanced ADHD subtypes. Second, a subset of the
subjects was pharmacologically treated in their daily life.
Third, all subjects mainly lived in Switzerland, which might
prevent comparability of our results with studies from other
countries. Finally, we had to exclude more ADHD subjects
than controls for the ERP analysis because of artifacts.
Taken together, we mainly replicated meta-analytic findings
in showing that ADHD subjects and controls moderately dif-
fered in terms of behavioral and neurophysiological measures
reflecting executive functions. Remarkably, this is a replication
within a large clinical dataset compromising a large age range
and a high heterogeneity within the ADHD group (ADHD
Figure 2. Overview of effect sizes for the behavioral and ERP-related measures. Cohen’s d reflects the magnitude of difference between
ADHD subjects and controls.
Note: Measures with significant interaction of group× age category are not represented (number of commission errors, mean reaction time,
and NoGoN2 latency).
Abbreviations: ERP, event-related potential; ADHD, attention-deficit/hyperactivity disorder; amp, amplitude; lat, latency.
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subtypes, symptomatic burden, and medication intake). The
obtained normalized group differences in terms of effect size
measures are small to moderate according to Cohen’s classifica-
tion. For example, assuming a normal distribution and a mod-
erate effect of d= 0.5 implies a substantial overlap of 80% of
the two groups. This demonstrates that none of the assessed
measures are useful as a sole biomarker for diagnosing
ADHD subjects. The low reliability and validity of the
ADHD diagnosis limit the comparisons of group means
between ADHD and healthy controls, especially of ERP mea-
sures—which reflect rather neurophysiological processing
divergence than obvious symptoms or behavioral deviations.
For a successful establishment of biomarkers in the clinical
setting, we need more complex approaches, combining multiple
neuronal and behavioral markers to distinguish ADHD and
healthy controls.20 However, as stated previously,48 a single
neurophysiological marker can reflect individual profiles of
specific functional impairments, which possibly show only
small differences, on the group level because of large inter-
individual variance, in both ADHD and healthy controls.
Moreover, the ERPs analyzed in this study may represent sum-
mations of hidden components, so that the decomposition of
those deflections into latent components by blind source sepa-
ration methods might enhance the effect sizes.49
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